Average stand-alone Part D premiums are projected to rise by less than $1 a month as a temporary subsidy program ends after 2026.
|Articles|August 3, 2012
Study: Generic Drugs Have Saved US $1Trillion
Advertisement
Generic drugs have saved the healthcare system more than $1 trillion over the last decade, according to research released Thursday by the generics industry.
The industry is pushing for expanded use of generics in Medicare and Medicaid, and the new research suggests that generics have helped control the government's spending on prescription drugs.
Read the full story:
Source: The Hill
Advertisement
Related to this article
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.
New data on atopic dermatitis show treatment gaps, heavy reliance on dermatology APPs, and wide state variation in specialist supply
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs
Aligning financial incentives with patient-centered care is becoming an increasingly complex path to navigate within oncology.
Panelists say drug price negotiation, Medicaid changes, prior authorization, and 340B reform strain community oncology.
MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
3
Oral Targeted Anticancer Medication Use Following High-Deductible Health Plan Enrollment
4
Preparing Practices for the Next Era of Hepatitis B Care
5